Regeneron: Q3 above expectations.
(CercleFinance.com) - Regeneron has had a good third quarter, with the group announcing results this Wednesday before New York opened, which were far better than the consensus.
The US pharmaceutical group posted a net income of 338 million dollars over the period, or 3.32 dollars per share, against 265 million dollars, or 2.27 dollars per share a year earlier. Adjusted EPS came in at 3.99 dollars, 17 cents above the consensus.
Meanwhile, revenues increased by more than expected to 1.5 billion dollars, after 1.22 billion dollars and against 1.45 billion dollars targeted by analysts.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The US pharmaceutical group posted a net income of 338 million dollars over the period, or 3.32 dollars per share, against 265 million dollars, or 2.27 dollars per share a year earlier. Adjusted EPS came in at 3.99 dollars, 17 cents above the consensus.
Meanwhile, revenues increased by more than expected to 1.5 billion dollars, after 1.22 billion dollars and against 1.45 billion dollars targeted by analysts.
Copyright (c) 2017 CercleFinance.com. All rights reserved.